Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

FLUIDITY Fighting Large-Scale Untreated Infectious Diseases with Innovative Treatments

Coordinator
Meletios Therapeutics, France
Runs
1 January 2023 to 31 December 2024
Status
Running
EU funding
€2.5m
Total cost
€4.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190144923

What the project is doing

In the project's own words, from its summary on CORDIS.

Founded in 2020, Meletios is developing innovative antiviral strategies to treat existing and emerging acute viral infections. Among those, our lead program, presented at the EIC Accelerator, is an oral Host-Directed Agent targeting cell mechanisms hijacked by viruses. By acting on cell membranes fluidity, our antiviral strongly limits cell internalization and intracellular trafficking of viruses. This approach could be effective against broad virus families, conferring our molecule with an advantageous broad-spectrum effect, a key strategy to boost our capacities to ward off outbreaks.

Moreover, our agent has immunomodulatory effects enabling to efficiently manage viral diseases by preventing excessive immune system reactions. We will perform an accelerated development process as our molecule has already proved it safety in humans. COVID-19 will be the first demonstrator of our molecules efficacy, before targeting diseases induced by other coronaviruses, influenza, flaviviruses.

Topics

Who is involved

OrganisationCityCountryRole
Meletios TherapeuticsParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI